Law Offices of Howard G. Smith announces an investigation on behalf of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (SUPN) - Get Report investors concerning the Company's possible violations of federal securities laws.
On November 9, 2020, after the market closed, Supernus disclosed receipt of a complete response letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding its new drug application ("NDA") for SPN-812 for the treatment of ADHD in pediatric patients aged 6-17 years old. According to the CRL, the NDA "is not ready for approval in its present form." Among other things, "[t]he primary issue cited in the SPN-812 CRL relates to the Company's in-house laboratory that conducts analytical testing, which recently moved to a new location."
On this news, Supernus's stock price fell $3.88 per share, or approximately 16%, to close at $21.08 per share on November 10, 2020, thereby injuring investors.
If you purchased Supernus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005355/en/